Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: 2 - You Need To See This

Coupled with macroeconomic headwinds, the sudden regional banking failures have marred investor sentiments. Moreover, amid anticipations of a recession, the existing market volatilities are not likely to subside anytime soon. Given this backdrop, we think the strong growth prospects of Gilead Sciences (GILD), Teva Pharmaceutical (TEVA), and MacroGenics (MGNX) make…

StockNews.com

3 Dividend Paying Stocks to Buy in March

With the stock market anticipated to stay volatile due to persistent concerns about high inflation, interest rate hikes, and a recession, fundamentally solid dividend stocks Gilead Sciences (GILD), CVS Health (CVS), and Altria (MO) might be great buys for a steady income stream. Keep reading.

StockNews.com

3 Nasdaq Stocks That Could Carry Your Portfolio for Years

With the broader market in trepidation amid the ongoing turmoil in the banking sector, fundamentally strong and resilient Nasdaq stocks Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Autodesk (ADSK) could be worth investing in for sustained risk-adjusted returns. Continue reading….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Value Stocks You Won't Regret Buying in 2023

With the Fed’s measures to counter inflation causing the collateral damage of asset price deflation, it could be wise to load up on Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), and DoubleDown Interactive (DDI), available at attractive valuations to capture future upside potential while limiting downside risks. Continue reading….

StockNews.com

2 Smart Dividend Stocks to Buy Now for Steady Gains

With the stock market expected to remain volatile due to persistent concerns about high inflation, interest rate hikes, and a recession, fundamentally strong dividend stocks Gilead Sciences (GILD) and Altria (MO) might be ideal choices to ensure a consistent income stream. Keep reading.

StockNews.com

4 "Strong Buy" Stocks to Buy Right Now

Strong economic data in recent weeks has raised signals of higher-than-expected hikes in the interest rate. Given the stalling disinflationary process, the stock market could remain volatile for some time. Thus, fundamentally strong stocks Gilead Sciences (GILD), HCA Healthcare (HCA), McKesson Corp. (MCK), and LSI Industries (LYTS) could be ideal…

StockNews.com

3 Stocks with Tremendous Growth Potential in 2023

Given the pace and intensity of the Fed’s monetary tightening, there’s a strong likelihood that the U.S. will enter a recession in 2023. However, amid a strong job market and resilient consumer spending, the possibility of a soft landing still stands. Given this backdrop, quality stocks Gilead Sciences (GILD), Coca-Cola…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

2 Dividend Stocks That Could Pay You for the Rest of Your Life

As the market remains volatile due to ongoing concerns about elevated inflation, prolonged rate hikes, and an impending recession, fundamentally strong dividend stocks Bristol-Myers Squibb (BMY) Gilead Sciences (GILD) might be ideal buys to ensure a stable income stream. Moreover, these stocks could be great long-term investments. Read more.

StockNews.com

1 Resilient Growth Stock to Buy Now and Hold Forever

Biopharmaceutical giant Gilead Sciences’ (GILD) shares have risen nearly 30% over the past year despite lingering macroeconomic challenges. Moreover, the company delivered solid growth last year and is expected to maintain its business momentum in 2023 and beyond, driven by its diversified medicines portfolio. Hence, investors could consider buying and…

StockNews.com

3 High-Value Stocks to Buy and Hold for a Lifetime

Despite showing signs of cooling, inflation is still well above the Fed’s 2% target. Moreover, January’s strong jobs report may encourage the Fed to raise interest rates even further, keeping the stock market highly volatile in the near term. Amid an uncertain macro environment, it could be wise to buy…

StockNews.com

KITE equips 19 lakh school children to handle fake news

Thiruvananthapuuram

The Hindu

3 Biotech Stocks to Buy for Q4 and 1 to Avoid

Favorable federal investments are anticipated to fuel further expansion in the biotech industry. Given the sector’s good prospects, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys. However, fundamentally weak stock Intra-Cellular Therapies (ITCI) might be best avoided. Read on….

StockNews.com

1 Stock Under $65 That You Shouldn't Ignore

Leading biopharmaceutical company Gilead Sciences (GILD) reported impressive sales in the last quarter and raised its full-year 2022 guidance. Furthermore, the company’s strategic acquisitions, drug approvals, and research breakthroughs should drive its growth in the coming quarters. Given GILD’s discounted valuation, we think it could be wise to buy this…

StockNews.com

Software Freedom Day: KITE to hold training sessions in Kerala districts on Sunday

Minister for General Education V. Sivankutty will inaugurate the training which is being organised jointly with the Democratic Alliance for Knowledge Freedom

The Hindu

Get all your
news in one place.

100's of premium titles.
One news app.

The Hindu

KITE, BSNL tie up for 100 Mbps broadband for school

12.5 times faster connectivity to be available in schools

Benzinga

Recap Of Friday's Biotech Catalysts - End Of The Day Summary

Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and relatlimab) for treatment of patients with Unresectable or Metastatic Melanoma based on results from the Phase 2/3 RELATIVITY-047 trial. Bristol Myers shares traded in a range of $72.48 to $73.61 on a…

The Hindu

KITE gets CM’s Award for Innovations in Public Policy

Thiruvananthapuram

StockNews.com

2 Oversold Stocks Investors Will Want to Buy Before They Blast Off

The stock market sell-offs triggered by macroeconomic and geopolitical issues since the beginning of the year have driven many quality stocks into the oversold territory. So, it could be wise to invest in oversold stocks Gilead Sciences (GILD) and Comcast (CMCSA), which have solid rebound potential. Let’s discuss….

Get all your
news in one place.

100's of premium titles.
One news app.

The Hindu

9,000 robotics kits for 2,000 high schools: Sivankutty

Thiruvananthapuram

The Hindu

Residential camps for Little KITEs students in Kerala from Saturday

Thiruvananthapuram

The Hindu

SchoolWiki plays a huge role in strengthening Malayalam in digital media: Kerala Speaker

Awards, citations presented to winners

The Hindu

School Wiki awards announced

MM UPS, Maakkootam, wins first prize of ₹1.5 lakh

The Times of India

Kochi: Little KITES to expand network

KOCHI: With the schools having reopened, Ernakulam unit of Kerala Infrastructure of Technology and Education (KITE) is revamping its activities and the works of Little KITES clubs in schools.

The Hindu

Digital profile of all students to be readied: Sivankutty

Thiruvananthapuram

StockNews.com

3 Low-Beta Stocks to Buy to Combat a Jittery Market

The Fed’s aggressive interest rate increases to tame multi-decade high inflation, and an anticipated economic slowdown, have exacerbated market volatility of late. To protect against the market uncertainties, we think investors should consider investing in low-beta stocks Merck (MRK), Gilead Sciences (GILD), and AmerisourceBergen (ABC). Let’s discuss why.

1 2 3

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

595 stories

Sristi Suman JayaswalThe

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.